Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Shares, par value CHF 0.08 per share
-
Shares outstanding
-
112M
-
Number of holders
-
59
-
Total 13F shares, excl. options
-
38.8M
-
Shares change
-
+2.21M
-
Total reported value, excl. options
-
$149M
-
Value change
-
+$3.75M
-
Put/Call ratio
-
1.45
-
Number of buys
-
34
-
Number of sells
-
-32
-
Price
-
$3.84
Significant Holders of ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) as of Q4 2022
81 filings reported holding ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share as of Q4 2022.
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) has 59 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.8M shares
of 112M outstanding shares and own 34.7% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (7.59M shares), FMR LLC (4.65M shares), MILLENNIUM MANAGEMENT LLC (3.4M shares), JPMORGAN CHASE & CO (3M shares), ALLIANCEBERNSTEIN L.P. (2.82M shares), GOLDMAN SACHS GROUP INC (2.16M shares), CITADEL ADVISORS LLC (1.99M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.88M shares), BANK OF AMERICA CORP /DE/ (1.6M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.49M shares).
This table shows the top 59 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.